Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
Kymera Therapeutics, Inc. (KYMR) reported a Q4 loss of $0.88 per share, missing the Zacks Consensus Estimate of a $0.76 loss. This is a significant increase from the $0.25 loss per share reported a year ago.
February 27, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kymera Therapeutics reported a larger-than-expected Q4 loss of $0.88 per share, missing the consensus estimate of $0.76. This marks a significant increase from the previous year's loss of $0.25 per share.
The reported loss per share of $0.88 is worse than the expected $0.76, indicating a negative earnings surprise. This, combined with a significant increase from the previous year's loss, is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100